Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
Nasus Pharma (NYSE: NSRX) has enrolled and dosed the first patient in a Phase 1 trial for NS003, its intranasal ondansetron formulation. Pre-clinical studies showed NS003's PK profile was comparable to IV ondansetron, with a favorable safety profile. The company aims to announce topline PK data before year-end and initiate a pivotal NS002 study for anaphylaxis in Q4. Ondansetron is widely used for chemotherapy-induced nausea and vomiting, with peak sales exceeding $1.5 billion in 2023.
How this was made
The 30-second read
Why it matters
The Phase 1 start reduces execution risk and provides a data point for future dosing and efficacy studies, potentially unlocking further financing.
Market read
First‑in‑human trial initiation is a material corporate event for a biotech, offering a modest trading catalyst.
What to watch
Funding runway and competitive landscape for anti‑emetic therapies may limit upside.
Background
Nasus Pharma focuses on needle‑free intranasal powder formulations for acute conditions, with NS003 targeting CINV/PONV and NS002 targeting anaphylaxis.
Ticker impact
Nasus Pharma announced first patient enrollment and dosing in Phase 1 PK trial of NS003, its intranasal ondansetron candidate.
potential modest upside as investors price in successful trial execution
Phase 1 initiation is a key milestone for biotech pipelines; markets typically react positively to forward movement.
Market effects
demonstrates continued interest in intranasal drug delivery, may boost related biotech peers.
limited to US‑listed biotech investors; no broader regional effect.
minor, confined to specialty pharma and drug‑delivery niche.
Counterpoint
Trial could encounter safety or PK issues, delaying or derailing the program.
Key entities
- companyNasus Pharma Ltd.
Clinical‑stage biotech developing intranasal drug candidates.
- executiveBrendan O'Grady
CEO of Nasus Pharma, quoted on trial progress.
